EU
Adult vaccination programmes deliver socio-economic benefits up to 19 times initial investment, according to new report
18 April 2024
Our new report examines the promise of prevention in healthcare and provides six key recommendations that could usher in a new era of optimised prevention.
Plan For A New EU Pharmaceutical Legislation: What Will It Mean For Pharmaceutical Innovation?
12 April 2024
The European Commission and European Parliament have set out their proposals for a reformed EU pharmaceutical legislation which could substantially change the incentive ecosystem for the first time in 20 years.
Breaking the European Deadlock: Part 3 – Revenue Guarantee and Subscription Models for New Antibiotics
16 January 2024
Insight 3 of this series provides an exploration of revenue guarantee/subscription models and how they could be implemented in the EU.
NGS testing for lung cancer across Europe still limited, despite clear case for adoption
10 July 2023
Our new report contains a wealth of evidence for clinical value and cost-saving potential of next-generation sequencing (NGS) testing in lung cancer, and recommends that increased uptake requires focus on reimbursement, national standardisation, and new infrastructure
New Drugs to Tackle Antimicrobial Resistance: Breaking the European Deadlock: Part 1 – Defining Objectives
25 May 2023
The EU Commission has set out important but controversial proposals for an AMR pull incentive for new antibiotics. In the first of this insight series, we set out seven objectives an EU fit-for-purpose pull incentive should work to achieve.
The Economics of Antibiotics – Part 4: What Does the Antibiotics Market of the Future Look Like?
12 October 2022
In this fourth and final blog in our AMR series, we set out a positive scenario for tackling antibiotic resistance, and contemplate other possibilities.
MoCA Initiative and its Value Framework: An Opportunity to Improve Decision Making for Orphan Drugs in Europe?
18 September 2018
Orphan drugs inherently face a number of challenges in their development and value assessment. In this blog post, we describe the Mechanism of Coordinated Action (MoCA)…
Routine Funding in the NHS in the UK of Medicines Authorised Between 2011 and 2016 via the European Centralised Procedure
1 December 2017
The centralised procedure was created in 1995 to facilitate access to innovative medicines across the European Union. Since then the scope of authorisation via the centralised…
Biosimilar Competition: Lessons from Europe and Prospects for the US
1 October 2014
Based on an OHE lunchtime seminar by Professor Henry Grabowski, this seminar briefing explores the lessons learned from Europe’s experience with biosimilars, and provides an analysis…